NYC medical weight loss

From W8MD weight loss and sleep centers

NYC medical weight loss options including GLP-1 injections, oral incretin medications, traditional diet pills, nutrition counseling, sleep medicine, and W8MD long-term maintenance care

NYC medical weight loss
NYC medical weight loss
NYC medical weight loss combines physician-supervised treatment, prescription medications, nutrition, sleep care, and long-term maintenance
Specialty Obesity medicine, medical weight loss, sleep medicine, nutrition, lifestyle medicine
Uses Obesity, overweight, weight loss, weight loss maintenance, insulin resistance, prediabetes, type 2 diabetes, sleep apnea, metabolic syndrome






Related W8MD Weight Loss, Sleep and MedSpa, personalized weight loss plan, GLP-1 maintenance therapy, long-term weight maintenance
NYC medical weight loss can help patients lose weight safely and build a long-term weight loss maintenance plan.
W8MD Weight Loss, Sleep and MedSpa has provided physician-supervised weight loss, sleep medicine, and wellness care since 2011.
Modern NYC medical weight loss may include GLP-1 weight loss injections, oral incretin medications, traditional diet pills, nutrition counseling, and customized maintenance care.
Meal replacements may help selected patients with protein intake, portion control, affordability, and structure.
W8MD success stories include patients who lost more than 100 pounds and maintained long-term results.
Sleep apnea evaluation is important because poor sleep can worsen hunger, cravings, fatigue, hypertension, and insulin resistance.

NYC medical weight loss refers to physician-supervised weight loss care in New York City for patients with obesity, overweight, insulin resistance, prediabetes, type 2 diabetes, metabolic syndrome, sleep apnea, hypertension, fatty liver disease, PCOS, and related conditions. Unlike commercial diet programs, medical weight loss evaluates the medical causes of weight gain and uses evidence-based tools such as nutrition counseling, meal replacements, anti-obesity medication, GLP-1 weight loss injections, incretin therapy, sleep apnea screening, and long-term weight loss maintenance.

W8MD Weight Loss, Sleep and MedSpa is a physician-supervised NYC medical weight loss, sleep, and wellness center established in 2011. W8MD has helped thousands of patients lose weight and keep it off, including major success stories such as a patient who lost over 165 pounds and other patients who lost over 100 pounds and maintained their results long term. W8MD serves New York City, Brooklyn, Queens, Manhattan, Staten Island, Long Island, New Jersey, Connecticut, and the greater New York metropolitan area.

Overview

NYC medical weight loss is designed for patients who need more than a generic diet. Many patients struggle with weight because of appetite biology, food noise, cravings, insulin resistance, poor sleep, untreated sleep apnea, medications, stress, menopause, limited time, cultural food patterns, repeated dieting, or metabolic adaptation after prior weight loss.

A medical weight loss program may include:

Why choose physician-supervised medical weight loss in NYC?

New York City patients often face long work hours, stress, restaurant eating, commuting, poor sleep, irregular schedules, and limited time for meal preparation. Physician-supervised medical weight loss can help by combining medical evaluation with realistic nutrition and medication options.

Physician supervision is especially important for patients with:

The National Institute of Diabetes and Digestive and Kidney Diseases notes that prescription weight-management medications may be used with lifestyle changes in selected adults with obesity or overweight and weight-related health problems.Prescription Medications to Treat Overweight and Obesity(link). National Institute of Diabetes and Digestive and Kidney Diseases.

W8MD NYC medical weight loss program

W8MD Weight Loss, Sleep and MedSpa provides an integrated approach that combines obesity medicine, medical weight loss, nutrition counseling, GLP-1 weight loss injections, traditional prescription medications, sleep medicine, meal replacements, and maintenance planning.

W8MD may help patients with:

Prescription weight loss options

Prescription weight-loss medications can be grouped into several categories. Some are FDA-approved for chronic weight management, some are approved for short-term use, and some are used off-label in selected patients. Medication choice depends on medical history, BMI, blood pressure, diabetes status, heart history, sleep, medications, pregnancy plans, insurance coverage, cost, side effects, and patient preference.

Current GLP-1 and incretin-based options

GLP-1 weight loss injections and related incretin therapy have transformed modern obesity medicine. These medications may reduce appetite, increase satiety, reduce food noise, slow gastric emptying, improve blood sugar control, and help selected patients lose significant weight.

Medication Brand names Type Main use Notes
Semaglutide Wegovy, Ozempic, Rybelsus GLP-1 receptor agonist Chronic weight management or diabetes depending on product Wegovy is used for chronic weight management; Ozempic and Rybelsus are primarily diabetes brands
Tirzepatide Zepbound, Mounjaro Dual GIP/GLP-1 receptor agonist Chronic weight management, diabetes, and OSA indication depending on product Zepbound is approved for chronic weight management and moderate-to-severe OSA in adults with obesity
Liraglutide Saxenda, Victoza GLP-1 receptor agonist Weight management or diabetes depending on product Saxenda is a daily injection for chronic weight management
Oral semaglutide Oral Wegovy, Rybelsus Oral GLP-1 receptor agonist Weight management or diabetes depending on product Wegovy tablets are FDA-approved for adult weight management
Orforglipron Foundayo Oral small-molecule GLP-1 receptor agonist Chronic weight management FDA-approved in 2026 for adults with obesity or overweight with weight-related comorbidity

The FDA approved Zepbound or tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related condition, together with reduced-calorie diet and increased physical activity.FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.

The FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.

The FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.

FDA labeling for Wegovy tablets states that oral semaglutide is indicated with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition.WEGOVY tablets prescribing information(link). U.S. Food and Drug Administration.

The FDA novel drug approvals list for 2026 includes Foundayo or orforglipron to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, in combination with reduced-calorie diet and increased physical activity.Novel Drug Approvals for 2026(link). U.S. Food and Drug Administration.

Traditional prescription diet pills

Traditional prescription diet pills remain useful for selected patients, especially those who are not candidates for GLP-1 therapy, need a lower-cost option, need combination maintenance, or respond well to appetite-suppressing medications.

Medication Brand or class Type Common role in medical weight loss
Phentermine Adipex-P and generics Sympathomimetic appetite suppressant Short-term appetite control in selected patients
Phentermine/topiramate Qsymia Combination medication Chronic weight management
Naltrexone/bupropion Contrave Appetite and reward pathway medication Chronic weight management, especially cravings in selected patients
Orlistat Xenical, Alli Gastrointestinal lipase inhibitor Reduces dietary fat absorption
Diethylpropion Tenuate and generics Sympathomimetic anorectic Short-term appetite suppression in selected patients
Phendimetrazine Bontril and generics Sympathomimetic anorectic Short-term appetite suppression in selected patients
Topiramate Generic Anticonvulsant used off-label May help cravings or binge-type eating in selected patients
Metformin Generic Insulin-sensitizing diabetes medication May help selected patients with insulin resistance, prediabetes, PCOS, or diabetes

The NIDDK lists FDA-approved long-term weight-management medications including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide.Prescription Medications to Treat Overweight and Obesity(link). National Institute of Diabetes and Digestive and Kidney Diseases.

DailyMed labeling for Contrave states that it is indicated as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition.CONTRAVE prescribing information(link). DailyMed, National Library of Medicine.

DailyMed labeling for phentermine notes that dosage should be individualized to obtain adequate response with the lowest effective dose.Phentermine hydrochloride tablet prescribing information(link). DailyMed, National Library of Medicine.

Emerging and investigational weight loss medications

The obesity medication pipeline is expanding rapidly. Emerging medications may offer oral dosing, monthly dosing, multiple hormone targets, or higher weight-loss potential. These should be considered investigational unless approved by the FDA.

Medication Developer/class Status Notes
Retatrutide Triple GIP/GLP-1/glucagon receptor agonist Investigational Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist; phase 3 trials have been reported or are ongoing
CagriSema Cagrilintide plus semaglutide Investigational or regulatory review depending on date Combination of an amylin analog and GLP-1 receptor agonist studied for obesity
Amycretin GLP-1 and amylin receptor agonist Investigational Also known as zenagamtide; under clinical development for obesity and type 2 diabetes
MariTide Maridebart cafraglutide Investigational Monthly or less frequent injectable therapy being studied for obesity and related conditions
Higher-dose or next-generation semaglutide products GLP-1 receptor agonist Product-specific status varies May be considered when FDA-approved and medically appropriate

Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist that activates receptors for GIP, GLP-1, and glucagon.What to know about retatrutide(link). Eli Lilly and Company.

A phase 2 trial of retatrutide published in the New England Journal of Medicine reported substantial weight reduction in adults with obesity over 48 weeks."Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

A 2025 New England Journal of Medicine trial reported that coadministered cagrilintide and semaglutide, or CagriSema, produced clinically meaningful body-weight reductions in adults with overweight or obesity compared with placebo."Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity".New England Journal of Medicine.2025;doi:10.1056/NEJMoa2502081.

Novo Nordisk has described amycretin, also known as zenagamtide, as a unimolecular GLP-1 and amylin receptor agonist under clinical development for adults with type 2 diabetes and adults with overweight or obesity.Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes(link). Novo Nordisk.June 5, 2026.

Amgen describes MariTide or maridebart cafraglutide as an investigational therapy being studied for obesity and obesity-related conditions.The Story of Maridebart Cafraglutide(link). Amgen.

How W8MD helps patients lose weight

W8MD helps patients by building a physician-supervised plan rather than relying on a single medication or generic diet. The program may combine medication, nutrition, sleep care, behavioral support, and maintenance.

W8MD may help with:

How W8MD helps patients keep weight off

Long-term success requires a maintenance plan. Many patients regain weight after stopping medication or losing follow-up structure. W8MD helps patients transition from active weight loss to maintenance.

Maintenance options may include:

  • GLP-1 maintenance therapy
  • Lowest effective dose strategy
  • Clinician-guided microdosing discussions
  • Extended interval dosing discussions when appropriate
  • Prescription diet pill maintenance when appropriate
  • Protein-first nutrition
  • Meal replacements
  • Weekly weight monitoring
  • Sleep apnea treatment
  • Strength training support
  • Early intervention for weight regain
  • Long-term follow-up visits

The STEP 1 trial extension found that after withdrawal of once-weekly semaglutide 2.4 mg and lifestyle intervention, participants regained a substantial portion of lost weight."Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension".Diabetes, Obesity and Metabolism.2022;PMID:35441470.PMC:9542252.

In SURMOUNT-4, continued tirzepatide helped maintain weight reduction, while withdrawal led to substantial weight regain in many participants."Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity".JAMA.2024;PMID:38078870.

W8MD success stories and testimonials

W8MD has helped thousands of patients since 2011. The program has reported major success stories, including a biggest-loser result of more than 165 pounds lost and multiple patients who lost over 100 pounds and maintained their results for years. Individual results vary, and no specific amount of weight loss can be guaranteed.

Featured W8MD patient success story

Fantastic program. Truly a life changer.

“FANTASTIC program! Truly a life changer! The first several months I lost on average 3 pounds a week. I have now lost 87 pounds in 10 months and I'm still losing! I can say it feels almost effortless, for with the elimination of most carbs plus the medication I have ZERO cravings and minimal hunger. My cholesterol, blood pressure, and blood sugar have all returned to normal having previously been considerably elevated. I look and feel twenty years younger (I am 57.) Staff is friendly and supportive, and the science works. I did not think that I would be able to achieve such results, and certainly not in less than a year. I am amazed at my success, and I could not have done it without Dr. Tumpati and W8MD.”

- D.M., actual W8MD patient who lost 100 lbs and has maintained the weight loss for over 10 years.

W8MD result themes

Patients who succeed with W8MD often report:

  • Reduced hunger
  • Reduced cravings
  • Less food noise
  • Better portion control
  • Improved energy
  • Improved blood pressure
  • Improved blood sugar
  • Improved cholesterol
  • Better sleep
  • Better mobility
  • More confidence
  • Long-term maintenance support

Affordable NYC medical weight loss options

Affordable NYC medical weight loss and GLP-1 options

W8MD Weight Loss, Sleep and MedSpa offers affordable physician-supervised medical weight-loss options for eligible patients.

  • Affordable GLP-1 options starting at $29.99/week and up with insurance for visits for eligible patients.
  • Most insurances accepted for qualifying medical visits.
  • Self-pay GLP-1 injection options starting from $59.99/week and up when available and medically appropriate.
  • Medication access, pricing, insurance coverage, prior authorization, and eligibility vary by patient, medication, pharmacy availability, location, and medical evaluation.

W8MD Brooklyn / NYC location

Location Address Phone Services Map
Brooklyn / New York City Weight Loss Center 2632 E 21st Street, Suite L3, Brooklyn, NY 11235 (718) 946-5500 Medical weight loss, GLP-1 weight loss injections, sleep medicine, MedSpa, nutrition counseling, meal replacements View map

NYC and nearby service areas

Who may benefit from NYC medical weight loss?

Patients may benefit if they have:

Safety and monitoring

Prescription weight-loss medications require medical supervision. W8MD may monitor:

  • Weight trend
  • Blood pressure
  • Pulse
  • Side effects
  • Appetite
  • Cravings
  • Blood sugar when appropriate
  • Constipation
  • Nausea
  • Hydration
  • Sleep symptoms
  • Medication interactions
  • Pregnancy plans when relevant
  • Maintenance readiness

Frequently asked questions

What is NYC medical weight loss?

NYC medical weight loss is physician-supervised treatment for obesity and overweight using medical evaluation, nutrition counseling, prescription medications, sleep care, and long-term maintenance.

Does W8MD offer GLP-1 weight loss injections in NYC?

Yes. W8MD can evaluate eligible patients for GLP-1 and incretin-based medications such as semaglutide, Wegovy, Ozempic, tirzepatide, Mounjaro, Zepbound, oral Wegovy, and Foundayo when medically appropriate.

Does W8MD offer traditional diet pills?

Yes. W8MD may evaluate selected patients for medications such as phentermine, phentermine/topiramate, Contrave, diethylpropion, phendimetrazine, topiramate, metformin, and other options when medically appropriate.

Can W8MD help patients keep weight off?

Yes. W8MD emphasizes long-term weight maintenance using follow-up care, nutrition counseling, meal replacements, GLP-1 maintenance therapy, clinician-guided microdosing discussions, prescription medication adjustment, and sleep apnea care.

Does W8MD help with sleep apnea?

Yes. W8MD provides sleep medicine services including sleep apnea screening and home sleep testing when appropriate. Treating sleep apnea can help improve fatigue, appetite control, blood pressure, and metabolic health.

Does W8MD accept insurance?

Yes. W8MD accepts most insurances for qualifying medical visits when coverage is available. Coverage varies by plan, diagnosis, medication, prior authorization rules, copay, and deductible.

What makes W8MD different from a commercial diet program?

W8MD uses physician-supervised obesity medicine, prescription medication options, sleep medicine, nutrition counseling, meal replacements, GLP-1 therapy when appropriate, and long-term maintenance planning rather than a one-size-fits-all diet.

Conclusion

NYC medical weight loss is a comprehensive, evidence-based approach for patients who want to lose weight safely and keep it off. W8MD Weight Loss, Sleep and MedSpa, established in 2011, has helped thousands of patients through physician-supervised obesity medicine, GLP-1 weight-loss injections, oral incretin medications, traditional diet pills, nutrition counseling, meal replacements, sleep apnea care, and personalized maintenance plans. With major patient success stories, including a biggest loser who lost over 165 pounds and patients such as D.M. who lost over 100 pounds and maintained long-term results, W8MD offers a practical medical pathway for New York City patients seeking lasting weight-loss success.

See also

Relevant WikiMD links

Further reading

  • Prescription Medications to Treat Overweight and Obesity(link). National Institute of Diabetes and Digestive and Kidney Diseases.
  • FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.
  • FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.
  • FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.
  • Novel Drug Approvals for 2026(link). U.S. Food and Drug Administration.
  • WEGOVY tablets prescribing information(link). U.S. Food and Drug Administration.
  • CONTRAVE prescribing information(link). DailyMed, National Library of Medicine.
  • Phentermine hydrochloride tablet prescribing information(link). DailyMed, National Library of Medicine.
  • "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension".Diabetes, Obesity and Metabolism.2022;PMID:35441470.PMC:9542252.
  • "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity".JAMA.2024;PMID:38078870.
  • "Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

External links


Retrieved from "https://w8md.com/w/index.php?title=NYC_medical_weight_loss&oldid=5964"